FIELD: biotechnology.
SUBSTANCE: invention relates to antigenic pneumococcal proteins, and can be used in medicine for vaccination against pneumococcal infection. Invention discloses a Streptococcus pneumoniae strain D39 mutant of pneumococcal surface protein A (PspA) with a substitute N254D, a DNA coding thereof and a vaccine containing said mutant.
EFFECT: invention enables to obtain a PspA mutant which does not undergo deamination and retains stability as a molecule even near a neutral pH range, wherein its antigenicity and ability to induce neutralizing antibody is not changed.
3 cl, 4 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PNEUMOCOCCAL VACCINE COMBINING SELECTED ALPHA HELICAL DOMAINS AND PROLINE-RICH DOMAINS OF PNEUMOCOCCAL SURFACE PROTEIN A | 2017 |
|
RU2794625C2 |
| VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | 2015 |
|
RU2735101C2 |
| SELF-ASSEMBLED NANOSTRUCTURED VACCINES | 2019 |
|
RU2811439C2 |
| FUSION PROTEIN | 2016 |
|
RU2748643C2 |
| TREATMENT AND PREVENTION OF ALLERGY TO HOUSE DUST MITES | 2019 |
|
RU2815386C2 |
| ANTIGENS AND ANTIGEN COMPOSITIONS | 2013 |
|
RU2727476C2 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| STABILIZED F RSV PROTEINS AND THEIR USE | 2019 |
|
RU2795459C2 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
